UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant To Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): July 18, 2013 (July 16, 2013)

 

 

HEALTHCARE REALTY TRUST INCORPORATED

(Exact Name of Registrant as Specified in Charter)

 

 

 

MARYLAND		001-11852		62-1507028
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

3310 West End Ave. Suite 700 Nashville, Tennessee 37203

(Address of principal executive offices) (Zip Code)

(615) 269-8175

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

---

Item 1.01. Entry into a Material Definitive Agreement

On July 16, 2013, Healthcare Realty Trust Incorporated (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC (the “Underwriter”), pursuant to which the Company agreed to issue and sell 3,000,000 shares of the Company’s common stock, par value $0.01 per share (“Common Stock”), in an underwritten public offering (the “Offering”). The net proceeds of the Offering, after underwriting discounts and commissions, will be approximately $78.4 million. The Company intends to use the net proceeds from the Offering for the acquisition of healthcare facilities, the repayment of outstanding borrowings on its unsecured credit facility, and other general corporate purposes. The closing of the transaction is subject to customary closing conditions and is expected to occur on or about July 19, 2013.

In connection with the Offering, certain of the directors and executive officers of the Company have agreed to enter into 30-day “lock-up” agreements in substantially the form attached to the Underwriting Agreement.

The Underwriter and/or its affiliates have provided and in the future may provide investment banking, commercial banking and/or advisory services to the Company from time to time for which it has received and in the future may receive customary fees and expenses and may have entered into and in the future may enter into other transactions with the Company. In particular, the Underwriter is a joint lead arranger and joint bookrunner under the Company’s unsecured credit facility. In addition, an affiliate of the Underwriter is a lender and the syndication agent under the Company’s unsecured credit facility and therefore will receive some of the net proceeds from the Offering through the repayment of borrowings under the credit facility.

The Offering is being made under a prospectus supplement and the accompanying prospectus filed with the Securities and Exchange Commission pursuant to the Company’s automatic shelf registration statement on Form S-3 (Registration No. 333-172368). The disclosure under this Item 1.01 is not an offer to sell, nor a solicitation of an offer to buy securities, nor shall there be any sales of these securities in any state or jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

The Underwriting Agreement is filed as Exhibit 1.1 to this Form 8-K and is incorporated herein by reference. The description of the material terms of the Underwriting Agreement is qualified in its entirety by reference to such exhibit.

Item 8.01. Other Events

The Company’s press release announcing the pricing of the Offering is filed as Exhibit 99.1 to this report and is incorporated herein by reference.

 

Item 9.01.

Financial Statements and Exhibits.

 

1.1		Underwriting Agreement dated July 16, 2013 by and between the Company and J.P. Morgan Securities LLC.
5.1		Opinion of Waller Lansden Dortch & Davis, LLP.
8.1		Tax opinion of Waller Lansden Dortch & Davis, LLP.
23.1		Consent of Waller Lansden Dortch & Davis, LLP (included in Exhibits 5.1 and 8.1).
99.1		Press release dated July 16, 2013.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: July 18, 2013